Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-906 in advanced HCC after sorafenib failure
NCT01101906Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Jan 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of linsitinib in hepatocellular carcinoma (HCC), sponsored by Astellas Pharma. Started Jan 2011; status: terminated.
02
Drugs
linsitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01101906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01101906.